MRK - Merck & Co Inc Stock Price, Fair Value and News

$101.45+1.59 (+1.59%)

Delayed as of 22 Nov 2024, 11:49 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MRK Price Action

Last 7 days

1.5%

Last 30 days

-6.4%

Last 90 days

-14.4%

Trailing 12 Months

-1.8%

MRK RSI Chart

MRK Valuation

Market Cap

252.5B

Price/Earnings (Trailing)

20.79

Price/Sales (Trailing)

EV/EBITDA

17.45

Price/Free Cashflow

17.02

MRK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRK Fundamentals

MRK Revenue

Revenue (TTM)

63.2B

Rev. Growth (Yr)

4.35%

Rev. Growth (Qtr)

3.38%

MRK Earnings

Earnings (TTM)

12.1B

Earnings Growth (Yr)

-33.47%

Earnings Growth (Qtr)

-42.13%

MRK Profitability

EBT Margin

21.72%

Return on Equity

27.26%

Return on Assets

10.34%

Free Cashflow Yield

5.88%

MRK Investor Care

Dividend Yield

2.93%

Dividend/Share (TTM)

2.96

Buy Backs (1Y)

0.17%

Diluted EPS (TTM)

4.77

MRK Alerts

Big fall in earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	61.4B	62.5B	63.2B	0
2023	57.9B	58.3B	59.3B	60.1B
2022	54.0B	57.2B	59.0B	59.3B
2021	41.0B	43.0B	45.2B	48.7B
2020	40.4B	38.0B	36.5B	42.4B
2019	43.1B	44.4B	46.0B	39.1B
2018	40.7B	41.3B	41.7B	42.3B
2017	39.9B	40.0B	39.8B	40.1B
2016	39.4B	39.4B	39.9B	39.8B
2015	41.4B	40.2B	39.8B	39.5B
2014	43.6B	43.5B	43.1B	42.2B
2013	46.2B	44.9B	44.5B	44.0B
2012	48.2B	48.4B	47.8B	47.3B
2011	46.1B	47.0B	47.8B	48.0B
2010	33.5B	38.9B	44.0B	46.0B
2009	0	0	0	27.4B

Get all data in R, Python etc through our Historical Stock Data APIs

About Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

CEO	Mr. Robert M. Davis J.D.
WEBSITE	merck.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers General
EMPLOYEES	65535

Merck & Co Inc Frequently Asked Questions

What is the ticker symbol for Merck & Co Inc? What does MRK stand for in stocks?

MRK is the stock ticker symbol of Merck & Co Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merck & Co Inc (MRK)?

As of Thu Nov 21 2024, market cap of Merck & Co Inc is 252.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers.

Is Merck & Co Inc a good stock to buy?

The fair value guage provides a quick view whether MRK is over valued or under valued. Whether Merck & Co Inc is cheap or expensive depends on the assumptions which impact Merck & Co Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRK.

What is Merck & Co Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, MRK's PE ratio (Price to Earnings) is 20.79 and Price to Sales (PS) ratio is 4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Merck & Co Inc's stock?

In the past 10 years, Merck & Co Inc has provided 0.059 (multiply by 100 for percentage) rate of return.